Abstract:BackgroundThe treatment status of small cell lung cancer (SCLC) in Mainland China has never been reported; therefore, this study is the first multicenter survey investigating the status of epidemiology and treatment options of SCLC in Mainland China.MethodsTwo questionnaires were designed to obtain information in 12 medical centers in five major Chinese cities. The hospital information questionnaire was designed to outline SCLC patients' characteristics and treatment preferences in each medical institution, and the patient information questionnaire collected detailed treatment information of 298 SCLC cases in these hospitals.ResultsSCLC represented 13.7% and 18.3% of all lung cancer patients in 2005 and 2010, respectively. Clinical management of SCLC follows mainstream clinical guidelines in general. The most widely applied first-line treatment mode for limited-stage patients was combined chemoradiotherapy (66.2%), while 77.0% of the extensive-stage patients received chemotherapy alone as initial treatment. Etoposide with cisplatin or carboplatin were the most accepted first-line chemotherapy regimens. The objective response rate was 58.3% after first-line chemotherapy and 23% of the patients who responded well to first-line treatment received prophylactic cranial irradiation. As for second-line chemotherapy, single regimen topotecan or a combined regimen containing topotecan were preferred (53.0%).ConclusionsThe treatment options indicated in our study are in accordance with the international clinical guidelines, which is valuable for the improvement of future guidelines, health care standard, and even the better distribution of health care resources in China.

Research progress on small cell lung cancer with syndrome of inappropriate secretion of antidiuretic hormone

Syndrome of Inappropriate Antidiuretic Hormone Secretion in Small Cell Lung Cancer

Clinical study on limited stage small cell lung cancer complicated by syndrome of inappropriate antidiuretic hormone secretion

A Narrative Review of Progress in Diagnosis and Treatment of Small Cell Lung Cancer Patients with Hyponatremia

Survival Outcomes and Surgical Intervention of Small Intestinal Neuroendocrine Tumors: a Population Based Retrospective Study

The syndrome of inappropriate antidiuretic hormone associated with nasal and paranasal malignant tumors

Advances in small intestinal neuroendocrine tumor treatment

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

Current Status and Progress of the Treatment of Limited-Disease Small Cell Lung Cancer

Research progress in the treatment of small cell lung cancer

Clinical characteristics of small-cell lung cancer complicated with hyponatremia

Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH

Current Small Cell Lung Cancer Treatment In China

Approach to the Patients with Adrenocortical Insufficiency Combined with the Syndrome of Inappropriate Secretion of Antidiuretic Hormone

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

[Recent Advances and Future Strategies for Small Cell Lung Cancer].

Current Perspective On The Pathogenesis Of Small Intestinal Neuroendocrine Tumors: Progress In Biomarkers And Molecular Events

Syndrome of inappropriate antidiuretic hormone release as the initial presentation of adenocarcinoma of the colon

SDH Mutations, As Potential Predictor of Chemotherapy Prognosis in Small Cell Lung Cancer Patients

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer

New insights into small‐cell lung cancer development and therapy